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Abstract 
To prevent chromosome segregation errors, the Spindle Assembly Checkpoint (SAC) delays 
mitosis exit until proper spindle assembly. We found that the FCP1 phosphatase and its downstream 
target WEE1 kinase oppose SAC, promoting mitosis exit despite malforme spindles. We further 
showed that targeting this pathway could be useful for cancer therapy.  
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Abbreviations 
 
SAC                      Spindle Assembly Checkpoint 
 
CDK1                     Cyclin-dependent kinase 1 
 
AMCDs                Anti-Microtubule Cancer Drugs 
 
MCL-1                    Myeloid cell leukemia 1     
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Mitosis is the fastest phase of the cell division cycle. Nevertheless, the safeguard mechanism 
Spindle Assembly Checkpoint (SAC) can delay mitosis exit until proper spindle formation.1 
Through still unclear mechanisms, however, an exceeding mitosis prolongation can translate into 
activation of the apoptotic programme.2 During the normal timing of mitosis, the cyclin B-
dependent kinase (CDK) 1 operates antiapoptotic measures like inhibitory phosphorylation of 
caspases.3 However, as time of mitosis is extended (for instance in case spindle assembly is 
hampered somehow), a progressive degradation of the antiapoptotic myeloid cell leukemia (MCL) 1 
protein appears to change drammatically cell sensitivity to apoptotic cell death.3,4 Indeed, it has 
been shown that impairing mitosis exit by depleting cells of CDC20, the crucial ubiquitin-ligase 
coactivator required for mitotic cyclins degradation and CDK1 inactivation, thus even in absence of 
spindle defects, promotes a prolonged mitotic arrest that ends up in a deadly fate.5  
Exposure of cells, expecially aneuploid cancer cells, to drugs that impair microtubule physiology 
and spindle assembly, like the widely used anti-microtubule cancer drugs (AMCDs) taxanes and 
vinka alcaloids, induces a SAC-dependent mitotic delay. At therapeutic concentrations, AMCDs 
appear to induce a very transient mitotic delay in cancer cells. Some cells die in mitosis but other 
appear to exit from mitosis despite malformed spindles.4,6 This is due to an adaptation-like 
mechanism by which cancer cells slip through SAC and exit mitosis abnormally and prematurely in 
the absence of a correctly assembled spindle. Slipped, and even more aneuploid, cells either stop 
dividing or die at later stages, however, it is possible they that may give rise to resistant clones.4,6 A 
recently developed  model suggests that, during AMCDs-induced prolonged mitosis, proapoptotic 
signals accumulate but cells may survive if they slip through mitosis before a certain proapoptotic 
signal threshold has been reached. Conversely, cells die if the threshold is reached before 
slippage.4,6 Thus, a better understanding of how cells slip through AMCDs-activated SAC may 
provide clues to improve AMCDs efficacy in cancer cell killing. 
By studying the mechanisms of mitosis exit, we previosly reported a novel, transcription-
independent, and crucial role for the essential RNA polymerase II-carboxy-terminal domain 
phosphatase FCP1 in bring about CDK1 inactivation at the end of mitosis.7 We identified cyclin 
degradation pathway components, like CDC20 and USP44, a deubiquitinating enzyme, and the 
CDK1 inhibitory kinase WEE1 as crucial FCP1 targets.7 At mitosis exit, FCP1 dephosphorylated 
WEE1, reactivating it to dampen down CDK1 activation, and CDC20 and USP44, to promote 
ubiquitin-dependent cyclin B degradation. 
Recently, we analysed the FCP1 relevance in SAC slippage and sensitivity to therapeutic AMCDs 
concentrations.8 We found that FCP1 affected SAC slippage, mitosis exit and cell death in the 
presence of AMCDs.  Depleting FCP1 protracted the time cells spent in mitosis in the presence of 
D
ow
nl
oa
de
d 
by
 [D
ipa
rtm
en
to 
di 
St
ud
i E
 R
eic
erc
he
], 
[D
om
en
ico
 G
rie
co
] a
t 0
5:4
7 3
0 J
un
e 2
01
5 
 3 
 
AMCDs.8 In addition, in FCP1-depleted AMCDs-treated cells, the levels of MCL-1 protein 
substantially decreased during prolonged mitosis and signficantly higher rates of apoptotic cell 
death were induced.8 In addition, we found that WEE1 was reactivated in an FCP1-dependent 
manner during prolonged mitosis in AMCDs-treated cells and had a crucial role in promoting SAC 
slippage by lowering CDK1 activity, otherwise required to sustain the SAC.9 Indeed, genetic or 
chemical WEE1 downregulation significantly extended mitosis and promoted cell death in several 
AMCDs-treated cancer cell lines and primary human adult lymphoblastic leukemia cells. Thus, the 
FWC (FCP1-WEE1-CDK1) pathway opposes the SAC and promotes slippage under AMCDs 
regimens. On the contrary, its inhibition prolongs mitotic duration, proapoptotic signals 
accumulation and eventually cell death in AMCDs-treated cancer cells.8 
WEE1 kinase is known to control the onset of mitosis by performing inhibitory phosphorylation of 
CDK1. WEE1 is also a crucial kinase that prevents mitosis onset in case cells have incompletely 
replicated or damaged DNA. Since it has been observed that forcing cells with damaged DNA into 
mitosis strongly promotes cell death, WEE1 inhibitors have been produced with the intent of an 
anticancer combination therapy with DNA damaging drugs and an orally available one is currently 
in clinical trials.10 Besed on our findings, we hypothesize that inhibiting WEE1 under AMCDs 
treatment would promote more efficient cancer cell killing by delaying slippage, thus, increasing 
the chances for proapoptotic signals accumulation (see Figure 1). Given the avaiability of a 
clinically usable WEE1 inhibitor, we sugget that it would be worth to perform clinical trials in 
which the WEE1 inhibitor is combined with AMCDs-based cancer therapy. Such a therapeutic 
combination would be particularly important in those clinical settings in which AMCDs are used as 
monotherapeutic agents as in the case of prostate cancer and several solid and hematological 
malignancies as second line treatments.  
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Figure 1 Impact of FCP1/WEE1 inhibition on anti-microtubule cancer drugs (AMCDs) 
treatment. The FCP1 phosphatase promotes mitosis exit during unperturbed mitosis as well as 
slippage through an AMCDs-activated spindle assembly checkpoint (SAC). Inhibiting FCP1 or its 
downstream WEE1 kinase can delay slippage, further extend mitosis and, giving proapoptotic 
signals more time to accumulate (or more time for degradation of antiapoptotic signals), increase 
chances for a deadly fate of AMCDs-treated cancer cells.  
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